Exec-Edge, Author at ExecEdge - Page 4 of 133

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part...

Enhanced Raises $50M to Fuel Next Phase, Backed by Major Investors

Enhanced Raises $50M to Fuel Next Phase, Backed by Major Investors

By Karen Roman Enhanced Group Inc. (NYSE: ENHA) said it closed a $50 million private investment in public equity financing. The transaction was led by Apeiron Investment Group, Enhanced co-founder and Chairman’s Christian Angermayer family office, as well as co-Founder...

Input your search keywords and press Enter.